Theonys
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Theonys (formerly Theon Therapeutics) was a Cambridge, Massachusetts patient-focused drug discovery company founded in 2020 by Nick Davis and Pete Dedon (MIT), Richard Gregory (Harvard) and Tom Begley (UAlbany) — world experts in tRNA network biology. It built the world's first end-to-end 'tRNA Operating System' (tOS) to discover CONTEXT Controllers: small-molecule modulators that pharmacologically program the translation of disease-causing proteins across oncogenic pathways, targeting cancer, chronic inflammation and rare immunometabolic disease. It raised $13.37M, backed by Leaps (Bayer), Xora Innovation (Temasek), Humboldt Fund, Emerson Collective and Alexandria Venture Investments, with 11+ employees.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Nick Davis, Pete Dedon (MIT), Richard Gregory (Harvard) and Tom Begley (UAlbany) launch Theonys in Cambridge, MA as a tRNA-based drug discovery company.
- Trademark filed
Theonys files a US trademark application (serial 90888056) covering pharmaceutical preparations and R&D services.
- Shutdown
Theonys shuts down in late 2022; its trademark is later assigned to 'TI ASSIGNEE, LLC' (an assignment-for-benefit-of-creditors vehicle) and abandoned.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.